Insulin therapy and type 2 diabetes: Management of weight gain

Journal of Clinical Hypertension

Volumn 11, Issue 10, 2009, Pages 601-607

  McFarlane, Samy I ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; MEGLITINIDE; METFORMIN; SIBUTRAMINE; SOMATOMEDIN B; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; BEHAVIOR CHANGE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; DIET THERAPY; EATING HABIT; EXERCISE; FAMILY HISTORY; FAST FOOD; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LOW CARBOHYDRATE DIET; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITION EDUCATION; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; ROUX Y ANASTOMOSIS; SIDE EFFECT; THERAPY DELAY; TREATMENT DURATION; WEIGHT CONTROL; WEIGHT GAIN; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DIET THERAPY; EXERCISE THERAPY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; OBESITY; WEIGHT GAIN;

EID: 70350257621     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2009.00063.x     Document Type: Review

References (48)

1. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18(suppl 3):S42-S49.
2. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: A preliminary report. Diabetes Care. 2004;27(1):17-20.
3. Nicasio J, McFarlane SI. Early insulin therapy and the risk of cardiovascular disease in type 2 diabetes. Therapy. 2005;2(5):685-688.
4. Meneghini L. Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J. 2007;100(2):164-174.
5. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028-1032.
6. Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: Delay of insulin therapy. J Gen Intern Med. 2007;22(4):453-458.
7. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673-2679.
8. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ. 2006;32(6):910-917.
9. Tibaldi J, Rakel RE. Why, when and how to initiate insulin therapy in patients with type 2 diabetes. Int J Clin Pract. 2007;61(4):633-644.
10. Straznicky NE, Eikelis N, Lambert EA, et al. Mediators of sympathetic activation in metabolic syndrome obesity. Curr Hypertens Rep. 2008;10(6):440-447.
11. Taylor AM. Cardiometabolic risk management in type 2 diabetes and obesity. Curr Diab Rep. 2008;8(5):345-352.
12. Addison S, Stas S, Hayden MR, et al. Insulin resistance and blood pressure. Curr Hypertens Rep. 2008;10(4):319-325.
13. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep. 2001;2(4):282-286.
14. Anthony K, Reed LJ, Dunn JT, et al. Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: The cerebral basis for impaired control of food intake in metabolic syndrome? Diabetes. 2006;55(11):2986-2992.
15. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2004;65(suppl):S23-S27.
16. Purnell JQ, Dev RK, Steffes MW, et al. Relationship of family history of type 2 diabetes, hypoglycemia, and autoantibodies to weight gain and lipids with intensive and conventional therapy in the Diabetes Control and Complications Trial. Diabetes. 2003;52(10):2623-2629.
17. Larger E. Weight gain and insulin treatment. Diabetes Metab. 2005;31(suppl 4, Pt 2):4S51-4S56.
18. Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: Review with meta-analysis of clinical studies. J Am Coll Nutr. 2003;22(5):331-339.
19. Schernthaner GH, Schernthaner G. Insulin resistance and inflammation in the early phase of type 2 diabetes: Potential for therapeutic intervention. Scand J Clin Lab Invest Suppl. 2005;240:30-40.
20. Murdolo G, Smith U. The dysregulated adipose tissue: A connecting link between insulin resistance, type 2 diabetes mellitus and atherosclerosis. Nutr Metab Cardiovasc Dis. 2006;16(suppl 1):S35-S38.
21. Heald AH, Karvestedt L, Anderson SG, et al. Low insulin-like growth factor-II levels predict weight gain in normal weight subjects with type 2 diabetes. Am J Med. 2006;119(2):e9-e15.
22. Renstrom F, Buren J, Svensson M, et al. Insulin resistance induced by high glucose and high insulin precedes insulin receptor substrate 1 protein depletion in human adipocytes. Metabolism. 2007;56(2):190-198.
23. Biesenbach G, Raml A, Alsaraji N. Weight gain and insulin requirement in type 2 diabetic patients during the first year after initiating insulin therapy dependent on baseline BMI. Diabetes Obes Metab. 2006;8(6):669-673.
24. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
25. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
26. Nichols GA, Gomez-Caminero A. Weight changes following the initiation of new anti-hyperglycaemic therapies. Diabetes Obes Metab. 2007;9(1):96-102.
27. Boule NG, Chaput JP, Doucet E, et al. Glucose homeostasis predicts weight gain: Prospective and clinical evidence. Diabetes Metab Res Rev. 2008;24(2):123-129.
28. Chaput JP, Tremblay A. The glucostatic theory of appetite control and the risk of obesity and diabetes. Int J Obes (Lond). 2009;33(1):46-53.
29. Salle A, Ryan M, Guilloteau G, et al. 'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients. Br J Nutr. 2005;94(6):931-937.
30. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7(1):56-64.
31. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-1274.
32. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28(10):1569-1581.
33. RašlováK, Tamer SC, Clauson P, et al. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig. 2007;27(4):279-285.
34. Rosenstock J, Davies M, Home PD, et al. Insulin detemir added to oral anti-diabetic drugs in type 2 diabetes provides glycemic control comparable to insulin glargine with less weight gain. Diabetes. 2006;55(suppl):A132.
35. Hermansen K, Davies M. Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab. 2007;9(3):209-217.
36. Fritsche A, Häring H. At last, a weight neutral insulin? Int J Obes. 2004;28(suppl 2):S41-S46.
37. Albu J, Raja-Khan N. The management of the obese diabetic patient. Prim Care. 2003;30(2):465-491.
38. Pereira MA, Kartashov AI, Ebbeling CB, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet. 2005;365(9453):36-42.
39. Westman EC, Yancy WS Jr, Mavropoulos JC, et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutr Metab (Lond). 2008;5:36.
40. Wilson PW, Black HR, Fabricatore AN, et al. Challenges to the diagnosis, evaluation, treatment, and management of clustered cardiometabolic risk factors. J Cardiometab Syndr. 2008;3(3):177-182.
41. Bonen A, Dohm GL, van Loon LJ. Lipid metabolism, exercise and insulin action. Essays Biochem. 2006;42:47-59.
42. Houmard JA. Intramuscular lipid oxidation and obesity. Am J Physiol Regul Integr Comp Physiol. 2008;294:R1111-R1116.
43. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61(3):523-528.
44. Dornhorst A, Luddeke HJ, Sreenan S, et al. Insulin detemir improves glycaemic control without weight gain in insulin-naive patients with type 2 diabetes: Subgroup analysis from the PREDICTIVE ™ study. Int J Clin Pract. 2008;62(4):659-665.
45. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
46. Van Gaal L, Gutkin S, Nauck M. Exploiting the antidiabetic properties of physiologic incretins to treat type 2 diabetes mellitus: Exenatide or insulin for patients with inadequate glycemic control using oral antidiabetic agents? Eur J Endocrinol. 2008;158:773-784.
47. Pratley RE, Salsali A. Inhibition of DPP-4: A new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007;23(4):919-931.
48. Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008;299(3):341-343.